Antibody Suppresses HIV in Infected Individuals
News Nov 14, 2016
The administration of VRC01, a potent and broadly neutralizing HIV-specific antibody, is safe, is well-tolerated, generated high plasma concentrations and modestly delayed the return of HIV viral rebound in HIV-1 infected individuals after they stopped receiving antiretroviral therapy, according to a study published in the New England Journal of Medicine by researchers at the University of Alabama at Birmingham, the National Institutes of Health and the University of Pennsylvania Penn Center for AIDS Research.
“Monoclonal antibodies are revolutionizing our approach to many diseases in oncology and rheumatology,” said Edgar T. Overton, M.D., co-director of the UAB Alabama Vaccine Research Clinic. “In this study, we tested whether a broadly neutralizing antibody against HIV could stop replicating virus. While a single antibody only modestly delayed viral rebound, we demonstrated that this strategy can be improved and potentially lead us to effective therapeutic HIV vaccine strategies. We are excited to pursue this approach in our ongoing efforts to end the HIV epidemic.”
Two clinical trials were conducted under the National Institutes of Health and the AIDS Clinical Trials Group in 24 HIV-1 infected individuals undergoing analytical treatment interruption, which measures changes in immunological response. The open-label trial in which both the researchers and participants were aware of the administered treatment showed that markers of HIV virus replication were suppressed for at least four weeks after the VRC01 was administered and HIV treatment was stopped, but all participants failed to maintain durable viral suppression in the absence of antiretroviral therapy.
Further studies looking at more potent antibodies and combinations of bNAbs like VRC01 will likely be required to achieve sustained remission of the virus in HIV-1 infected individuals after halting ART.
“We are excited to be on the forefront of the global efforts to end AIDS,” Overton said.
Story from University of Alabama at Birmingham. Original piece written by Alicia Rohan. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., … Chun, T.-W. (2016). Effect of HIV antibody VRC01 on viral rebound after treatment interruption. New England Journal of Medicine. doi:10.1056/nejmoa1608243
Malaria Prevention: New Antibody Targets Unique Binding SiteNews
Scientists have discovered a human antibody that, when tested in mice, prevented malaria infection by binding a specific portion of a surface protein found in almost all strains of the malaria parasite worldwide.READ MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Combination Drug Trial Launched to Eradicate B-Cell MalignanciesNews
Researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined effectiveness of a standard of care drug with a novel monoclonal antibody that target B-cell malignancies, which include leukemias and lymphomas.READ MORE
Comments | 0 ADD COMMENT
International Conference on Neuroimmunology, Neurological disorders and Neurogenetics
Sep 26 - Sep 27, 2018